Abstract
Bladder dysfunction entails overactive bladder (OAB) defined as symptoms of urinary urgency, frequency, and/or nocturia with or without incontinence if there is no obvious pathology or infection or lower urinary tract symptoms that includes recognized causes of bladder dysfunction.
Literature search.
Symptoms of OAB are reported in about 15% of the adult US population. This is increased 2- to 3-fold in patients with congestive heart failure (CHF), hypertension, cardiovascular disease (CVD), chronic kidney disease (CKD), or the elderly where it often accompanies prescription for short, rapid-acting loop diuretics. However, less than 2% of patients seeking care for OAB receive treatment. The fear of urinary incontinence from short, rapid-acting loop diuretics may contribute to medication nonadherence and less well-controlled, apparently resistant hypertension. The bladder contracts to rapid stretch. Thus, less rapid-acting diuretics such as thiazides or extended-release formulations of loop diuretics may be preferable for those with bladder dysfunction. Alternatively, the use of a mineralocorticosteroid receptor antagonist, angiotensin receptor antagonist/neprilysin inhibitor, or sodium glucose-linked transport type 2 inhibitor may allow a reduction in the dose of a short, rapid-acting loop diuretic for those with bladder dysfunction.
A worsening of symptoms from bladder dysfunction by short, rapid-acting loop diuretics occurs frequently in patients with CVD, CHF, hypertension, and CKD where it can contribute to impaired quality of life and poor adherence and thereby to worsening outcomes.
